Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Linjuan Zeng, Zhongqiu Lin et al.|Nature Medicine|2024Cited by 41
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Mansoor Raza Mirza, Jianqing Zhu et al.|EClinicalMedicine|2024Cited by 24